Manfidokimab

曼多奇单抗

Report date: 2026/02/25 13:44:00

Base Information

Drug NameManfidokimab
Drug Alias NameAK-120 (Akeso )
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsDermatitis, AtopicAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustraliaMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncAkesobio Australia Pty LtdZhongshan Akeso Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A